Diagnostic Evaluation of Polycystic Ovary Syndrome in Adolescents - UpToDate

21/10/2020 Diagnostic evaluation of polycystic ovary syndrome in adolescents - UpToDate
Author: Robert L Rosenfield, MD

Section Editors: Mitchell E Geffner, MD, Amy B Middleman, MD, MPH, MS Ed
Deputy Editor: Alison G Hoppin, MD
Contributor Disclosures
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Sep 2020. | This topic last updated: Jul 27, 2020.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common cause of infertility in women [1],
frequently becomes manifest during adolescence, and is primarily characterized by ovulatory
dysfunction and androgen excess (hyperandrogenism). The syndrome is heterogeneous
clinically and biochemically. The diagnosis of PCOS has lifelong implications with increased
risk for metabolic syndrome, type 2 diabetes mellitus, and possibly cardiovascular disease and
endometrial carcinoma. PCOS should be considered in any adolescent girl presenting with a
chief complaint of hirsutism, treatment-resistant acne, menstrual irregularity, acanthosis
nigricans, and/or obesity.
The diagnostic evaluation of an adolescent with suspected PCOS is described here. Other
aspects of PCOS in adolescents are reviewed separately:
● (See "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome
in adolescents".)
● (See "Treatment of polycystic ovary syndrome in adolescents".)
● (See "Etiology and pathophysiology of polycystic ovary syndrome in adolescents".)
INDICATIONS FOR EVALUATION
Work-up for PCOS is recommended for adolescent girls with one or more of the following
characteristics:
● An abnormal degree of hirsutism or a hirsutism equivalent, such as inflammatory acne

vulgaris, that is poorly responsive to topical therapies or oral antibiotics
● Focal hirsutism (localized areas of excessive sexual hair growth), if this is accompanied by
menstrual abnormality
uptodate.searchbox.science/contents/diagnostic-evaluation-of-polycystic-ovary-syndrome-in-adolescents?search=pcos&source=search_result&selec… 1/31
● Menstrual abnormality (persistent amenorrhea or oligomenorrhea, or excessive uterine

bleeding) ( table 1)
Acanthosis nigricans and/or obesity are manifestations of insulin resistance and metabolic
syndrome and may be the presenting complaint of PCOS. Examination will usually reveal
some of the above classical symptoms or signs, but occasionally these may not develop for
some time. Thus, in the absence of risk factors for PCOS, such as a family history of PCOS, one
may choose to defer a work-up of these latter patients for PCOS and instead observe them for
the emergence of clinical evidence of PCOS over time. (See "Definition, clinical features, and
differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Clinical
features'.)
EVALUATION OVERVIEW
We suggest a stepwise approach to the evaluation that addresses the diagnostic criteria (
table 2) [2]. This approach is first outlined here and then detailed in the sections below (
algorithm 1).
● Basic evaluation – The evaluation begins with a focused clinical evaluation for symptoms
and signs suggestive of PCOS: menstrual irregularity, hirsutism (or hirsutism equivalents,
such as acne), and acanthosis nigricans. This is followed by laboratory testing for
hyperandrogenemia, starting with measurement of total or free testosterone as outlined
in the algorithm ( algorithm 1). Elevated total or free testosterone levels are very
suggestive of PCOS. (See 'History and physical examination' below and 'Screening tests to
detect common causes of abnormal menses' below.)
Patients with elevated testosterone should be further evaluated with a screening panel of
laboratory tests to rule out other common non-PCOS causes of hyperandrogenemia (
algorithm 2) [3]. This evaluation excludes the vast majority of disorders that mimic
PCOS.
I also generally include ultrasonography of the ovaries and adrenal glands in the work-up
of hyperandrogenic females, primarily to evaluate for rare tumors of these organs. Some
other experts reserve the ultrasonographic screening for those patients with atypical
features suggestive of virilization, such as rapidly progressive hirsutism, clitoromegaly, or
hirsutism or menstrual abnormality that fails to respond to therapy. (See 'Screening tests
to exclude common non-PCOS causes of hyperandrogenemia' below.)
In my pediatric endocrinology practice, I typically order most of these screening tests

during the first visit. I take this approach because I consider it to be both simple and an
economical use of time for most patients. However, measurement of serum 17-
hydroxyprogesterone (17OHP) and other steroids requires early-morning sampling to be
highly discriminatory in detecting nonclassic congenital adrenal hyperplasia (NCCAH).
Some other experts perform the tests serially or select among the tests based on clinical
symptoms and signs that raise concerns for a particular disorder.
● Diagnosis – Demonstration of persistent hyperandrogenism in a patient with a

persistently abnormal degree of menstrual irregularity fulfills the diagnostic criteria for
PCOS, provided that the endocrine screening tests are negative for disorders that mimic
PCOS. This minimalist approach is approximately 99 percent specific for PCOS in young
women and meets international consensus criteria for the diagnosis of PCOS in
adolescents [4-7]. (See 'Diagnosis' below.)
Lack of hyperandrogenemia effectively rules out the diagnosis of PCOS in adolescents.

However, the ovarian hyperandrogenism of PCOS may not become demonstrable until a
few years after menarche [8,9]. Thus, young patients with menstrual irregularity should
be followed, and the diagnosis of PCOS should not be dismissed until their menses
normalize and androgen levels remain persistently normal.
● Further endocrine evaluation – The basic evaluation described above does not exclude
rare virilizing disorders ( table 3) [10-12]. In the presence of concern about the
possibility of a rare virilizing disorder, such as a tumor or rare congenital disorder, a more
comprehensive evaluation is suggested, including dexamethasone suppression testing
and cosyntropin testing, which determine the source of androgen ( algorithm 3). These
tests also help to exclude the possibility that a mild PCOS picture is due to obesity and
would be expected to respond to simple weight-control measures alone. This approach is
consistent with the hirsutism clinical practice guidelines from the Endocrine Society [12].
(See 'Further endocrine evaluation for rare disorders mimicking PCOS' below.)
● Additional evaluation after the diagnosis of PCOS – Girls diagnosed with PCOS should
have additional evaluations for glucose intolerance and other features of the metabolic
syndrome, particularly if they are obese. Primary relatives of PCOS patients may also
benefit from screening for these disorders. (See 'Additional evaluation of PCOS patients'
below and 'Evaluation of family members' below.)
BASIC DIAGNOSTIC APPROACH
History and physical examination — The evaluation starts with a thorough assessment of

the clinical symptoms and signs suggestive of hyperandrogenism and anovulation (ie, for
disorders that mimic PCOS ( algorithm 1)). The cutaneous manifestations of
hyperandrogenism (particularly hirsutism and acne, which occur in approximately three-
quarters of PCOS cases) provide clinical evidence of hyperandrogenism. An abnormal
menstrual pattern constitutes evidence of oligo-anovulation.
● Hirsutism – The degree and distribution of sexual hair growth should be documented
using the Ferriman-Gallwey score ( figure 1). An adult level of hirsutism ordinarily is
reached by two years after menarche [5]. Hirsutism should be interpreted in the context
of norms for the patient's ethnicity. Moderate or severe hirsutism (hirsutism score >15)
constitutes clinical evidence of hyperandrogenism in an adolescent [4-6]. The history
should specifically explore whether the patient shaves excess hair or uses depilatory
agents, which may obscure the physical findings, and whether the patient is taking
medications that cause hirsutism (eg, anabolic-androgenic steroids, valproic acid). (See
"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in
adolescents", section on 'Hirsutism'.)
● Acne – The degree of acne should be evaluated in the context of the patient's gynecologic
age. The possibility of hyperandrogenism is suggested by moderate or severe
inflammatory acne (>10 lesions in any area, eg, face, chest, back ( table 4)) through the
perimenarcheal years or acne that is persistent and poorly responsive to topical or oral
antibiotic dermatologic therapy [4-6]. (See "Definition, clinical features, and differential
diagnosis of polycystic ovary syndrome in adolescents", section on 'Acne'.)
● Menses – The age of menarche and subsequent menstrual patterns should be described
and interpreted in the context of the patient's gynecologic age. The types of menstrual
dysfunction that suggest abnormal degrees of anovulation in adolescence are detailed in
the table ( table 1) [2]. A menstrual pattern that is outside of these bounds for two
years (or one year with supporting evidence for PCOS) can be considered a "persistent"
abnormality and fulfills one of the two criteria for the diagnosis of PCOS [2,4-6]. Note that
normal menstrual regularity does not necessarily mean that ovulatory function is normal.
(See "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome
in adolescents", section on 'Anovulation'.)
● Obesity and acanthosis nigricans – Obesity or acanthosis nigricans are often the initial
complaint, though not the only PCOS symptom elucidated upon review of systems and
examination. (See "Definition, clinical features, and differential diagnosis of polycystic
ovary syndrome in adolescents".)
● Other – Assessment should include a history of medications that may either mask the
symptoms (eg, oral contraceptives and topical or systemic acne medications) or cause the
symptoms (eg, anabolic-androgenic steroids, valproic acid for epilepsy). Assessment
should also include evaluation for features that suggest a hyperandrogenic disorder other
than PCOS, including virilization (eg, rapidly progressive hirsutism), galactorrhea,
Cushingoid or acromegaloid changes, evidence of thyroid dysfunction, or a family history
of hyperandrogenic disorders ( algorithm 1). (See "Definition, clinical features, and
differential diagnosis of polycystic ovary syndrome in adolescents", section on 'Differential
diagnosis'.)
Testing for hyperandrogenemia — Testing for testosterone and/or free testosterone should

be included in the initial evaluation of a patient with clinical symptoms and signs suggesting
PCOS ( algorithm 1). However, these tests are only reliable for females if they are performed
in a specialty laboratory using a highly sensitive and specific assay. Combined estrogen-
progestin oral contraceptives (COCs) previously started should be withdrawn for two to three
months before screening for PCOS because they suppress testosterone production. Current or
recent use of systemic glucocorticoids also may moderately suppress total and free
testosterone. Testing methods and interpretation are discussed below.
If a reliable testosterone assay is not available, the presence of moderate or severe hirsutism
is approximately 85 percent specific for hyperandrogenism and may be used as clinical
evidence for hyperandrogenism [4-6]. Mild hirsutism is a less reliable criterion for
hyperandrogenism because only approximately one-half of patients with mild hirsutism have
hyperandrogenemia, three-quarters of whom have a coincident menstrual abnormality [12].
For patients with severe or rapidly progressive hyperandrogenism, measurement of

dehydroepiandrosterone sulfate (DHEAS) should be included in the initial evaluation to screen
for a virilizing adrenal tumor.
Patients who have clinical features consistent with PCOS but have an initial normal total
testosterone level, should have repeat testing measuring an early-morning (8 AM) serum free
testosterone level in a reliable specialty laboratory by dialysis, or calculated from total
testosterone and sex hormone-binding globulin (SHBG).
Considerations for testosterone assays — Persistent serum testosterone elevation above

adult norms in a specialty reference laboratory is the best single test for hyperandrogenemia
in postmenarcheal females [4-6].
The choice between testing for the presence of hyperandrogenemia with assay of total or free
testosterone depends on assay reliability and cost-effectiveness considerations [12]. If a
reliable measurement of total testosterone is easily available, this can be used as an initial test
but should be followed by measurement of free testosterone if the results are not consistent
with the patient's clinical course. If a reliable method for measuring serum free (or
bioavailable) testosterone is available to the practitioner, and cost is not a significant issue,
this test is the preferred choice for initial testing.
There are many pitfalls in testosterone assays at the low levels found in women, and reliable
testosterone assays are not available to many clinicians. For these and other reasons
discussed below, assessment may be best deferred to a specialist.
● Total testosterone – Reliable total testosterone assays are critical to accurate assessment
for biochemical evidence of hyperandrogenism. This is important to obtain specificity for
testosterone versus other steroids that cross-react in assays at the relatively low levels
present in women and children. Their availability is limited to major specialty laboratories.
Liquid chromatography-mass spectrometry methods are becoming the preferred method
[13]. Where this technology is not available, high-quality postchromatographic
radioimmunoassays yield comparable results and are the method of choice [6].
The automated assays that are used to measure serum total testosterone in most
laboratories are not suitable to accurately measure levels in females [14,15]. Results by
the best available assays vary by an average of approximately 6 to 26 percent [11,16]. The
interpretation of the laboratory results is further complicated by systematic differences
between assays and excessively broad normal ranges derived from populations of
apparently normal women with unrecognized androgen excess.
● Free testosterone – An elevation of serum (or plasma) free testosterone is the single most
sensitive test to establish the presence of hyperandrogenemia [4,12,15,17,18].
• The serum free testosterone concentration is approximately 50 percent more

sensitive for the detection of hyperandrogenemia than the total testosterone
concentration. This is because PCOS is characterized by low levels of SHBG, which is
the main determinant of the fraction of serum testosterone that is weakly bound to
albumin and the fraction that is free from protein binding, and thus ultimately
bioactive [19,20]. Consequently, the combination of an upper-normal total
testosterone and a lower-normal SHBG yields a high free testosterone concentration.
SHBG production by the liver is raised by estrogen and hyperthyroidism, and it is
suppressed in the settings of hyperandrogenemia and/or hyperinsulinemia (seen
with obesity-induced insulin resistance) [21]. Although the low SHBG in obese
individuals has been attributed to hyperinsulinemia [22], evidence suggests that
excess glucose and fructose intake themselves and inflammatory cytokines mediate
the SHBG reduction in patients with obesity [23].
• The most accurate free testosterone determinations come from specialty laboratories
using established, validated assays in well-characterized control women. This is
because lack of uniform assay methodology and standards introduces systematic
differences between assays.
• Direct assays of the serum free testosterone concentration are inaccurate and should
be avoided [12].
• The only reliable methods report free testosterone that is calculated as the product of
the total testosterone and a function of SHBG (free testosterone = total testosterone
× percent free testosterone) [12,24]. The most accurate methods calculate percent
free testosterone as determined by equilibrium dialysis or, alternatively, as calculated
from the SHBG concentration [25]. An alternative reliable method is to calculate
"bioavailable testosterone" by determining the percent of serum testosterone not
precipitated with globulins by ammonium sulfate (the supernatant includes both the
fraction free and that weakly bound to albumin, the latter being bioactive to the
extent that it dissociates to free in a given tissue space dependent upon the local
interstitial albumin concentration) [24].
Interpretation of testosterone levels — The normal upper limit for serum total

testosterone in adult women is approximately 40 to 60 ng/dL (1.4 to 2.1 nmol/L) when using
most validated assays [15,17,18]. The adult norm is the appropriate reference range for
adolescents [4,5]. Most patients with PCOS have serum testosterone concentrations of 29 to
150 ng/dL (1 to 5.2 nmol/L). A total testosterone >150 ng/dL (5.1 nmol/L) increases the
likelihood of a virilizing ovarian or adrenal neoplasm: this cut-off has approximately 90
percent sensitivity and 80 percent specificity for androgen-producing tumors in adults [26].
For practical purposes, an elevated serum total and/or free testosterone at any time of day
provides evidence of hyperandrogenism in an anovulatory cycle. However, a normal level in
the afternoon does not exclude hyperandrogenemia. This is partly because serum
testosterone undergoes episodic changes of approximately twofold (trough-to-peak). It is also
partly because norms are standardized for early morning (8 AM) on days 4 through 10 of the
menstrual cycle in regularly cycling women as normal testosterone levels fall 10 percent from
8 AM to 4 PM and double during midcycle [27,28].
The estrogen and progestin contents of COCs interfere with the assessment of androgens.
They suppress gonadotropins, elevate SHBG, and directly inhibit steroidogenic enzymes such
as 3-beta-hydroxysteroid dehydrogenase. They normalize androgens in PCOS and also have

been reported to normalize androgens in some virilizing tumors [29]. After discontinuing
COCs, normal women may transiently have a slightly high total testosterone level but a
normal free testosterone level because SHBG turnover is slower than testosterone turnover.
Screening tests to detect common causes of abnormal menses — Most patients

presenting for evaluation of hyperandrogenism have a menstrual abnormality for which
screening for other causes of anovulatory disorders is indicated ( algorithm 1). (See "Causes
of primary amenorrhea" and "Epidemiology and causes of secondary amenorrhea".)
Initial screening for patients with a menstrual abnormality should include:
● Beta-human chorionic gonadotropin (beta-hCG) – Pregnancy should be excluded in all

anovulatory patients.
● Chronic disease panel – Complete blood count, erythrocyte sedimentation rate or C-

reactive protein (CRP), and comprehensive metabolic profile screen for chronic diseases
that can cause anovulation.
● Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) – Slightly elevated

LH and slightly low FSH are characteristic of typical PCOS. Markedly elevated FSH suggests
primary hypogonadism, whereas low LH indicates secondary hypogonadism (eg, a
pituitary tumor). Glucocorticoids suppress gonadotropin levels.
● Prolactin – Hyperprolactinemia is a cause of gonadotropin deficiency; it is not

accompanied by galactorrhea if the gonadotropin deficiency is profound.
● Thyroid-stimulating hormone (TSH) – Normal serum TSH levels are ordinarily adequate
to rule out thyroid dysfunction, which causes menstrual dysfunction. Hypothyroidism may
cause confusion with hyperandrogenism by causing coarsening of hair (which can be
mistaken for hirsutism [5]), lowering SHBG, and causing multicystic ovaries.
Hyperthyroidism may confound the diagnosis of hyperandrogenism by raising SHBG,
which may elevate the total testosterone. Note that mildly elevated levels of TSH are often
found in obese individuals, but this is a consequence rather than a cause of the obesity
and is reversible if weight loss can be achieved. (See "Acquired hypothyroidism in
childhood and adolescence".)
Screening tests to exclude common non-PCOS causes of hyperandrogenemia — If serum

testosterone and/or free testosterone is elevated, the next step is to exclude most non-PCOS
causes of hyperandrogenemia. Adult and adolescent specialty society guidelines for the
diagnosis of PCOS differ slightly as to which tests should be routinely obtained versus which
tests should be considered only in those patients with suggestive clinical features of disorders
that may mimic PCOS [4,30-33]. Consequently, expert practice varies regarding the extent and
timing of further laboratory evaluation. In my practice, I routinely perform a simple screening
battery of endocrine tests and ultrasonography at this stage ( algorithm 2 and table 3).
Other experts perform these tests in selected patients with atypical features, such as
virilization (to rule out virilizing neoplasm), central obesity (to rule out Cushing syndrome), or
acromegaloid features.
Endocrine screening panel — In patients with PCOS, the following endocrine studies will
be normal. An abnormal result, however, for any of these tests suggests another cause of
hyperandrogenism (see "Definition, clinical features, and differential diagnosis of polycystic
ovary syndrome in adolescents", section on 'Differential diagnosis') and should be further
evaluated as suggested in the linked topic reviews.
● Early-morning 17-hydroxyprogesterone (17OHP) – An 8 AM 17OHP level is a good

screening test for nonclassic congenital adrenal hyperplasia (NCCAH) secondary to 21-
hydroxylase deficiency when performed under properly controlled circumstances:
• Early-morning sampling is critical to detect the 17OHP elevation of NCCAH because it

wanes rapidly thereafter due to the diurnal variation of adrenal steroid secretion.
• It is important to obtain the screening sample when the patient is amenorrheic or

within the first 10 days after the start of a menstrual cycle in regularly cycling patients
because 17OHP rises during the preovulatory and luteal phases of the cycle. A 17OHP
value of >170 ng/dL (5.1 nmol/L) is suggestive of NCCAH in an anovulatory cycle but is
also compatible with recent ovulation. This cutoff displayed approximately 95 percent
sensitivity and 90 percent specificity in detecting NCCAH, with the main confounder
being PCOS (>20 percent of patients with PCOS have elevated baseline 17OHP
concentrations, as do some with tumoral hyperandrogenism) [34-37]. An abnormal
screening test is not diagnostic but requires a cosyntropin (ACTH) stimulation test to
confirm the diagnosis of CAH [38], unless the basal 17OHP level is >1000 ng/dL (30
nmol/L) [38]. (See 'Further endocrine evaluation for rare disorders mimicking PCOS'
below.)
• I also measure serum progesterone at the same time as the 17OHP measurement to
rule out the possibility that the patient has unexpectedly ovulated (which occurs in
approximately 10 percent of oligo-amenorrheic PCOS patients) and is unknowingly
being tested in the luteal phase of her cycle. The luteal phase is indicated by a serum
progesterone >175 ng/dL (5.5 nmol/L) and can be accompanied by 17OHP levels up to
350 ng/dL (10.5 nmol/L).
• In those patients with known CAH that is complicated by PCOS (see "Etiology and
pathophysiology of polycystic ovary syndrome in adolescents", section on 'Congenital
virilization'), full glucocorticoid replacement treatment will suppress the 17OHP level
to normal, but androgen levels will remain slightly elevated. (See "Etiology and
pathophysiology of polycystic ovary syndrome in adolescents", section on 'Congenital
virilization'.)
● Other androgens – DHEAS is included primarily to screen for an adrenal tumor. Routine
testing for other androgenic steroids, such as androstenedione, has been of little
diagnostic utility in most populations [12]. It is a marker for adrenal hyperandrogenism
and has little diurnal variation. While the most common cause of DHEAS elevation is the
functional adrenal hyperandrogenism of PCOS [39], the main purpose of measuring
DHEAS levels is to rapidly identify an unusual virilizing adrenal disorder, such as cortisone
reductase deficiency [40,41] or an adrenal tumor. Girls with a virilizing tumor usually
present with a rapid onset of virilizing features, and DHEAS levels are often, but not
necessarily, markedly elevated (>700 mcg/dL, 19 micromol/L) if the tumor is of adrenal
origin. CAH seldom causes severe DHEAS elevation [39]. However, in a substantial
minority of patients with virilizing tumors, the symptoms are indolent in onset and mimic
PCOS in presentation (see "Definition, clinical features, and differential diagnosis of
polycystic ovary syndrome in adolescents", section on 'Differential diagnosis' and "Adrenal
hyperandrogenism"). COCs have equivocal effects on the DHEAS level. (See "Normal
adrenarche".)
The measurement of other androgens, such as androstenedione, is ordinarily of little

diagnostic utility, except in situations of diagnostic uncertainty [12].
● Prolactin – Prolactin should be measured at this stage if it was not done in the initial
panel of screening tests for abnormal menses. Androgen excess occurs in 40 percent of
hyperprolactinemic women due to multiple effects of prolactin excess on adrenal
androgen production and androgen metabolism, and the great majority (approximately
85 percent) of these women have galactorrhea [42]. The combination of hirsutism,
galactorrhea, and amenorrhea is sometimes described as Forbes-Albright syndrome.
Prolactin elevation is unusual in PCOS itself, occurring in less than 1 percent of subjects,
and marginal elevation in the absence of specific clinical evidence does not necessitate a
prolactinoma work-up [33,43]. Serum prolactin values more than 25 ng/mL usually have
an identifiable cause rather than PCOS [43]. Estrogenic medications increase prolactin
uptodate.searchbox.science/contents/diagnostic-evaluation-of-polycystic-ovary-syndrome-in-adolescents?search=pcos&source=search_result&sele… 10/31
secretion, but the amount of estrogen in low-dose COCs generally does not cause
hyperprolactinemia. (See "Definition, clinical features, and differential diagnosis of
polycystic ovary syndrome in adolescents", section on 'Differential diagnosis' and "Clinical
manifestations and evaluation of hyperprolactinemia".)
● Serum cortisol – Serum cortisol is an optional test that many experts perform only for
hyperandrogenic patients with central obesity. The purpose is to screen for endogenous
Cushing syndrome (due to adrenal hyperplasia or adrenal tumors), which is sometimes
associated with adrenal overproduction of testosterone. Although the normal range for
serum cortisol is wide (5 to 25 mcg/dL), a serum cortisol concentration of <10 mcg/dL (276
nmol/L) is reassuring evidence against endogenous Cushing syndrome. A midday or
afternoon sample is more optimal for this screening than an early-morning sample.
Patients with markedly elevated serum cortisol levels or those with clinical features
suggestive of Cushing disease warrant further evaluation (eg, with 24-hour urine
collection for free cortisol and creatinine). Estrogen raises total serum cortisol levels by
increasing cortisol-binding globulin, but low-dose COCs do not generally cause falsely
abnormal results. (See "Establishing the diagnosis of Cushing's syndrome".)
● Insulin-like growth factor 1 (IGF-1) – This is an optional test that many experts perform
only for hyperandrogenic patients with gigantism or acromegaloid features. Elevated IGF-
1 distinguishes growth hormone (GH) excess as a cause of hyperandrogenism [44] from
the pseudoacromegalic hyperandrogenism of severe insulin resistance syndromes [45].
GH excess usually can be identified by clinical symptoms (gigantism in growing children
or acromegaly after epiphyseal fusion) in teenagers and adults. However, the author has
seen acromegaly first present with PCOS-like symptoms. The oral estrogen of COCs may
lower IGF-1 levels sufficiently to obscure the diagnosis of acromegaly. (See "Diagnosis of
acromegaly".)
Ultrasonography — The primary purpose of ultrasonography in the hyperandrogenemic

adolescent is to exclude causes other than PCOS. A secondary benefit is to identify the few
individuals with very large ovaries, for whom it simply provides further evidence of PCOS
severity and diagnostic specificity, as discussed below. Ultrasonography is neither
recommended nor required for the diagnosis of PCOS in adolescents, because the high
frequency of polycystic-appearing ovaries in normal females in this age group makes this an
unreliable criterion for the diagnosis of PCOS [46].
● The role of ultrasonography in the differential diagnosis of PCOS – Practice varies as

to the indications for ultrasonography in girls with confirmed hyperandrogenemia since
ultrasonography is not recommended for the diagnosis of PCOS. In my pediatric
endocrinology practice, I have recommended ovarian and adrenal ultrasonography for all
patients with anovulatory symptoms and documented hyperandrogenemia to exclude
rare but serious androgen-producing tumors, as described below. Other experts perform
ultrasonography only for selected patients with features that are atypical for PCOS, such
as very high testosterone levels (eg, >150 ng/dL), clitoromegaly, rapidly progressive
hirsutism, or poor response to treatment [47].
The primary purpose of ultrasonography is to screen for the rare but serious ovarian
tumor ( algorithm 2). In addition, other pelvic pathology, including an ovotesticular
disorder of sex development and the functional hyperandrogenism of pregnancy, may be
detected by ultrasonography. On rare occasions, ultrasonography has been insensitive in
detecting a virilizing ovarian tumor in adults [48,49]. It may also reveal a virilizing
adrenocortical tumor and, if there is reason to suspect this, more specialized imaging
studies are indicated (see "Clinical presentation and evaluation of adrenocortical
tumors"). Girls who have an ultrasound that shows an ovarian tumor or other explanation
for hyperandrogenism should be referred for further evaluation and treatment of the
underlying disorder. Otherwise, hyperandrogenic girls need further endocrine studies
irrespective of whether the ovaries are polycystic, as discussed in the section above. (See
'Endocrine screening panel' above.)
Ultrasonography also provides the opportunity for patient reassurance and education.
For many women, the diagnosis of ovarian "cysts" raises a concern about tumors, so it is
reassuring to know that a tumor has been ruled out by the ultrasound. The clinician can
explain to the PCOS patient with a polycystic ovary that these are numerous small egg
sacs that are not ovulating properly. Conversely, if a polycystic ovary is not visualized in a
PCOS patient, the clinician can explain that the ovarian dysfunction is "too mild to be seen
on the ultrasound."
● Ultrasonographic criteria for polycystic ovary morphology (PCOM) – The

ultrasonographic finding of PCOM is supportive of a diagnosis of PCOS, but it is not
included in the 2015 diagnostic criteria for PCOS in adolescents [4-6]. This is because of
uncertainties about the definitive criteria for PCOM in this age group. However, there is
reason to believe that the presence of clear PCOM, in combination with symptomatic
hyperandrogenism in the absence of anovulatory symptoms, poses a risk for PCOS in an
adolescent [50]. Therefore, we suggest careful follow-up of girls with PCOM. In adults,
these same features would meet a somewhat nonspecific PCOS criterion. (See "Definition,
clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents",
section on 'Adults'.)
International consensus criteria for adults define PCOM on the basis of either excessive
size or follicle number (or both) in the absence of a dominant-sized follicle (>1 mL) or a
corpus luteum, as evaluated by transvaginal ultrasonography ( image 1) [32,51] (see
"Diagnosis of polycystic ovary syndrome in adults", section on 'Transvaginal ultrasound').
On the one hand, there is a high prevalence of PCOM in the most clinically severe PCOS
cases [50]. On the other hand, PCOM is a common normal variant in asymptomatic
women that may predict a slightly longer period of fertility [50]. Furthermore, it has
become apparent that these criteria are problematic in young adults because they
naturally have slightly larger ovaries [52], and the newer high-definition vaginal imaging
techniques show that small antral follicle counts up to 24 are normal [53].
Adult PCOM criteria are especially problematic when applied to adolescents [4,5]. For one
thing, an accurate antral follicle count cannot be defined by the abdominal
ultrasonographic approach necessary in virginal adolescents [53,54]. For another, even if
an accurate follicle count is obtained by magnetic resonance imaging (MRI), the adult
criteria for PCOM overlap with criteria for a multifollicular ovary. A multifollicular ovary is
defined by the presence of ≥6 follicles of 4 to 10 mm diameter without increase in ovarian
volume, and is known to be a normal variant unrelated to hyperandrogenism [4].
Additionally, studies suggest that ovarian volume is slightly larger in adolescents than in
adults, though data vary considerably [4,50,54]. Consequently, one-quarter to one-half of
normal adolescents meet adult criteria for PCOM [54,55]. In 2015, an international
consensus group proposed using an ovarian volume >12 mL to constitute PCOM in
adolescence [4]. However, this threshold may be too low since a study of 102 adolescents
with normal cycles found that 13 percent had PCOM by this criterion [56]. These findings
are consistent with the evidence that a mean ovarian volume (average of both ovaries) up
to 12 mL or a single ovarian volume up to 14 to 15 mL may be normal in adolescents
[5,50,54,55].
DIAGNOSIS
PCOS can be diagnosed in a patient with a persistently abnormal uterine bleeding pattern
and evidence of hyperandrogenism ( table 2) after exclusion of other causes of most non-
PCOS causes of hyperandrogenemia ( table 3). Most clinical guidelines recommend
screening for nonclassic congenital adrenal hyperplasia (NCCAH), Cushing's syndrome,
prolactin excess, thyroid dysfunction, and acromegaly. However, the guidelines vary as to
which tests are recommended for universal screening and which are recommended only for
patients with symptoms suggestive of one of these disorders. These guidelines are based on
expert opinion. Therefore, the actual range of practice varies considerably among expert
clinicians in this field.
It is also best to confirm the persistence of hyperandrogenism in order to avoid labeling as

PCOS adolescents who have transient hyperandrogenemia due to physiologic adolescent
anovulation [4] (see "Definition, clinical features, and differential diagnosis of polycystic ovary
syndrome in adolescents", section on 'Differential diagnosis'). Approximately one-quarter of
adolescents with an abnormal degree of menstrual irregularity will have an elevated
androgen level but no clinical manifestations of hyperandrogenism, and neither the
hyperandrogenemia nor the menstrual abnormality will persist. In the absence of clinical
signs of hyperandrogenism (eg, hirsutism or an abnormal degree of acne), a diagnosis of
PCOS is not warranted in an adolescent with anovulatory symptoms and an elevated
androgen level without other clinical manifestations of PCOS, unless both of these features
are documented to persist for two years [4,5].
Adolescents with PCOS or with features of PCOS that do not fulfill diagnostic criteria should be
followed to determine that hyperandrogenemia and symptoms persist since data are limited
on the natural history of adolescent PCOS. The diagnosis of PCOS should not be fully
dismissed until menses normalize and androgen levels remain persistently normal.
FURTHER ENDOCRINE EVALUATION FOR RARE DISORDERS MIMICKING

PCOS
Some endocrinologists perform additional testing in hyperandrogenemic patients to detect

disorders that mimic PCOS and would go undetected by the above basic screening approach.
These disorders include the approximately 1 percent or less who have a rare virilizing disorder
that may be encountered no more than a few times in an endocrinologist's career ( table 3),
and the 8 percent in whom simple obesity may account for a mild PCOS picture in the absence
of ovarian androgenic dysfunction [11]. This diagnostic approach is consistent with that
recommended by hirsutism guidelines from the Endocrine Society for evaluation of hirsute
women with hyperandrogenemia [12], but the cost effectiveness is unknown. (See "Definition,
clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents",
section on 'Differential diagnosis'.)
Our suggested approach to a more comprehensive diagnostic endocrine evaluation (

algorithm 3) is typically performed only in selected patients during an evaluation by a
subspecialist (eg, a pediatric or reproductive endocrinologist). This evaluation may be
particularly helpful in patients with atypical features, such as virilization (eg, rapidly
progressive hirsutism), unexplained congenital or familial hyperandrogenism, or

unresponsiveness to standard therapy. Our approach augments the initial evaluation by
starting with a dexamethasone androgen-suppression test (DAST) to distinguish an
adrenocorticotropic hormone (ACTH)-dependent adrenal source of androgen excess from
other sources of androgen ( algorithm 3) [10]. If indicated by these tests or atypical clinical
or laboratory findings, further work-up may also include specialized imaging studies such as
computed adrenal tomography [12]. (See "Definition, clinical features, and differential
diagnosis of polycystic ovary syndrome in adolescents", section on 'Other' and "Clinical
presentation and evaluation of adrenocortical tumors".)
Dexamethasone androgen-suppression test — The responses of androgens (testosterone

and dehydroepiandrosterone sulfate [DHEAS]) and glucocorticoids to dexamethasone
suppression are the primary outcome measures to establish the underlying source of
hyperandrogenism ( algorithm 3). Normal responses in our laboratory are given in the
algorithm legend.
● Baseline levels of steroid intermediates, such as 17-hydroxypregnenolone (17OHP), 11-

deoxycortisol, and androstenedione, are very elevated in rare forms of congenital adrenal
hyperplasia (CAH) and some virilizing tumors. Baseline 24-hour urine glucocorticoids (ie,
free cortisol and 17-alpha-hydroxycorticosteroids) with creatinine are helpful for the
unusual case of Cushing's syndrome and the rare case of cortisone reductase deficiency.
The latter is characterized by elevated urinary 17-alpha-hydroxycorticosteroid excretion
that is comprised predominantly of cortisone rather than cortisol metabolites [40].
● A short (four-hour) DAST can be used to screen for an ovarian source of androgen in
obese women [11]. This consists of a noontime 0.5 mg oral dose of dexamethasone
followed by blood sampling four hours later for cortisol, DHEAS, and testosterone. A short
DAST is 95 percent sensitive for detecting the functional ovarian hyperandrogenism of
PCOS. Therefore, normal suppression of plasma testosterone by a short DAST rules out
PCOS with high probability. However, subnormal testosterone suppression in response to
a short DAST cannot be expected to distinguish virilizing disorders or Cushing's syndrome
from PCOS.
● A long (four-day) DAST is the definitive form of dexamethasone suppression testing for
the differential diagnosis of hyperandrogenic disorders.
● The DAST is interpreted as follows:
• If testosterone excess is not suppressed by dexamethasone, but cortisol and DHEAS

are suppressed normally, the diagnosis of PCOS is virtually assured. However,
virilizing tumor and adrenal rests must still be considered in the presence of
suggestive clinical factors.
• If neither androgen (testosterone and DHEAS) excess nor glucocorticoids are

suppressed normally by dexamethasone, then disorders other than PCOS must be
considered, such as Cushing's syndrome, adrenal tumors, and glucocorticoid
resistance (or dexamethasone was not taken properly). If the levels of androgens
suggest an adrenal tumor, further imaging, such as computed tomography, is
indicated.
• If both androgens (testosterone and DHEAS) and glucocorticoids are suppressed

normally, an ovarian source for androgen is unlikely, so further evaluation for adrenal
disorders is indicated with a cosyntropin (ACTH) test for CAH.
Cosyntropin (ACTH) stimulation test — The responses of steroid intermediates on the

pathway to cortisol and androgens distinguish adrenal steroidogenic disorders that mimic
PCOS ( algorithm 3).
● The cosyntropin (ACTH) stimulation test (using a 250 mcg dose, with samples drawn 30 to
60 minutes later) is interpreted as follows:
• A 17OHP value >1000 ng/dL (30 nmol/L) is highly suggestive, and >1500 ng/dL is
definitive for the 21-hydroxylase deficiency form of nonclassic congenital adrenal
hyperplasia (NCCAH) [57]. Intermediate 17OHP levels (1000 to 1500 ng/dL) require
genetic confirmation to make a definitive diagnosis of NCCAH [37,58]. (See "Diagnosis
and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-
hydroxylase deficiency".)
• Mildly elevated responses of 17-hydroxypregnenolone and DHEA are characteristic of

the primary functional adrenal hyperandrogenism of PCOS and are often confused
with nonclassic 3-beta-hydroxysteroid dehydrogenase deficiency (3-beta-HSD) [59].
Only when the 17-hydroxypregnenolone response to ACTH is >10 standard deviation
(SD) above the normal mean (ie, >4500 ng/dL [150 nmol/L]) has nonclassic 3-beta-
HSD been documented by mutation analysis in hirsute females [60]. (See "Definition,
clinical features, and differential diagnosis of polycystic ovary syndrome in
adolescents", section on 'Differential diagnosis' and "Etiology and pathophysiology of
polycystic ovary syndrome in adolescents", section on 'Functional adrenal
hyperandrogenism'.)
• Nonclassic 11-beta-hydroxylase deficiency is a rare mime of PCOS [61]. Only an 11-

deoxycortisol response to ACTH >5 times greater than the upper limit of normal
(>4000 ng/dL/116 nmol/L) has been shown to be specific for mutation detection. (See
"Definition, clinical features, and differential diagnosis of polycystic ovary syndrome
in adolescents", section on 'Differential diagnosis'.)
If both the DAST and the ACTH stimulation test are normal, obesity or idiopathic
hyperandrogenism is most likely. The most common cause of this may be the pseudo-PCOS of
obesity [11] (see "Definition, clinical features, and differential diagnosis of polycystic ovary
syndrome in adolescents", section on 'Differential diagnosis'). The rare possibility of cortisone
reductase deficiency should be considered on the basis of the clinical picture. (See
"Dexamethasone suppression tests" and "Initial testing for adrenal insufficiency: Basal cortisol
and the ACTH stimulation test".)
Ancillary tests
● Serum levels of anti-müllerian hormone (AMH) are mildly increased in subjects with
polycystic ovary morphology (PCOM; a category that includes both normal adolescents
and PCOS subjects) [55,62,63], while AMH elevations of twofold or more above the upper
normal limit are highly specific for PCOS [62]. AMH is a product of the granulosa cells of
small growing follicles that normally restrains follicular growth and sex steroid secretion
[64,65]; thus, it acts as an intraovarian paracrine gatekeeper to control the recruitment of
resting primordial follicles into the growth phase [55,62,63]. Androgen excess in the ovary
stimulates primordial follicle growth, causing an increase in antral follicle count that
contributes to PCOM. Thus, AMH levels are independently related on the one hand to the
size of the follicle pool ("follicle reserve" [62,66]) and PCOM (for which AMH has been
suggested as a surrogate for ultrasonographic criteria to define PCOM), and on the other
hand hyperandrogenism. (See "Etiology and pathophysiology of polycystic ovary
syndrome in adolescents", section on 'Primary functional ovarian hyperandrogenism'.)
● Gonadotropin-releasing hormone (GnRH) agonist test – In patients with PCOS,

administration of a GnRH agonist induces a hyperresponsive elevation of 17OHP without
evidence of a steroidogenic block. The steroid pattern in response to the test
distinguishes PCOS from other causes, particularly rare hyperandrogenic disorders of
steroidogenesis, such as nonclassic 3-beta-hydroxysteroid dehydrogenase deficiency. The
test is performed by administering leuprolide acetate 10 mcg/kg subcutaneously and
measuring steroid levels 20 to 24 hours later; the test can be performed in conjunction
with dexamethasone administration (as part of the DAST described above) to suppress
coincidental adrenal secretion that might interfere in the interpretation [67,68]. This test
may facilitate the early diagnosis of PCOS in adolescents [69]. It also helps in determining
if mild PCOS is simply due to obesity, which is suggested when hyperandrogenemia is
mild, and serum luteinizing hormone (LH), AMH, and DHEAS, along with ovarian
morphology, are normal [11]. (See "Definition, clinical features, and differential diagnosis
of polycystic ovary syndrome in adolescents", section on 'Differential diagnosis' and
"Uncommon congenital adrenal hyperplasias", section on '3-beta-hydroxysteroid
dehydrogenase type 2 deficiency'.)
ADDITIONAL EVALUATION OF PCOS PATIENTS
Once a diagnosis of PCOS has been established, the possibility of insulin-resistance

manifestations should be considered. This is because PCOS is a risk factor for the early
development of type 2 diabetes mellitus, metabolic syndrome, and their associated risks, such
as sleep-disordered breathing [70,71]. Approximately one-quarter of teenagers with PCOS
meet proposed adolescent criteria for the metabolic syndrome. Patients should also be
evaluated for quality-of-life issues. (See "Definition, clinical features, and differential diagnosis
of polycystic ovary syndrome in adolescents", section on 'Manifestations of insulin resistance'
and "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in
adolescents", section on 'Psychological issues'.)
We advise screening for type 2 diabetes mellitus in adolescents with PCOS and obesity, or
other risk factors for diabetes mellitus. At the least, a fasting plasma glucose or hemoglobin
A1c should be measured. However, an oral glucose tolerance test (OGTT) is preferable
because it is the most sensitive and specific measure of glucose tolerance (see "Epidemiology,
presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents", section
on 'Screening'). This recommendation is consistent with those made in an international
reproductive endocrinology consensus publication [72], the American Association of Clinical
Endocrinologists (AACE), and the minority position of the Androgen Excess and PCOS Society
(AE-PCOS) in adult women with PCOS [73,74]. The prevalence of diabetes was reported to be 2
percent based on the fasting blood sugar in one series, and 8 percent when based on OGTT
criteria in another series of adolescents [75,76]. In both series, almost all of the adolescents
had no symptoms of diabetes. Impaired glucose tolerance suggests insulin resistance and is a
risk factor for type 2 diabetes mellitus and cardiovascular disease. Thus, an abnormal OGTT
has important therapeutic implications. (See "Treatment of polycystic ovary syndrome in
adolescents", section on 'Obesity and insulin resistance'.)
Glucose tolerance should be monitored regularly because a substantial number of women

with PCOS will experience deterioration in glucose tolerance. As an example, among 25
adolescent and young women followed for a mean of 34 months, the two-hour plasma
glucose during an OGTT increased at an average rate of 9 mg/dL (0.5 mmol/L) per year [77].
Among the 14 women with PCOS and normal glucose tolerance at baseline, 55 percent
experienced deterioration of glucose tolerance when they were retested with an OGTT.
Among the 14 women with PCOS and impaired glucose tolerance at baseline, 29 percent
progressed to diabetes.
Patients should also be evaluated for quality-of-life issues. (See "Definition, clinical features,
and differential diagnosis of polycystic ovary syndrome in adolescents", section on
'Psychological issues'.)
PCOS is a risk factor for endometrial carcinoma in young women [78]. The basis of the risk is
multifactorial: it is related to the endometrial hyperplasia that arises from persistent estrogen
stimulation without the progesterone-induced inhibition of proliferation and differentiation to
secretory endometrium that occurs after ovulation. Hyperandrogenism, insulin-resistant
hyperinsulinemia, and the inflammatory changes of obesity appear to be aggravating factors
for endometrial carcinoma in women with PCOS; risk also seems related to body mass index
(BMI)-independent proto-oncogenic changes in endometrial cells [79]. (See "Clinical
manifestations of polycystic ovary syndrome in adults", section on 'Endometrial cancer risk'.)
EVALUATION OF FAMILY MEMBERS
Parents and siblings of PCOS patients are at increased risk for metabolic syndrome and
diabetes mellitus, particularly if they are obese. Screening can be accomplished by
measurement of hemoglobin A1c or oral glucose tolerance testing (OGTT) in first-degree
relatives of either sex. Premenopausal mothers and sisters are at risk for PCOS and should be
screened for those features.
These recommendations are prompted by the high prevalence of PCOS and metabolic
syndrome among immediate relatives of individuals with PCOS (see "Etiology and
pathophysiology of polycystic ovary syndrome in adolescents", section on 'Heritable traits').
According to one study, approximately one-half of sisters of PCOS probands have an elevated
serum testosterone level, and one-half of these (one-quarter of the total) in turn have
menstrual irregularity and thus meet National Institutes of Health (NIH) criteria for PCOS [80].
In another study, approximately one-quarter of sisters met the Androgen Excess and PCOS
Society (AE-PCOS) criteria for PCOS, having hyperandrogenism and a polycystic ovary,
although menses were ovulatory [81]. The likelihood of a mother having PCOS seems similar:
22 percent in our series [75].
The prevalence of metabolic syndrome or diabetes mellitus in parents of women with PCOS is
higher than in parents of women without PCOS. In our series, one-third or more of mothers
and the great majority of fathers had metabolic syndrome and diabetes mellitus [75]. Notably,
the diabetes was asymptomatic in one-half and was uncovered by glucose tolerance testing.
Meta-analysis has demonstrated a significantly greater prevalence of type 2 diabetes mellitus
and insulin resistance in the parents of PCOS patients and a trend to diabetes and insulin
resistance in siblings [82].
OTHER RESOURCES
The following online resources are available to patients with PCOS and their families:
● PCOS resources for a healthier you – From the Center for Young Women's Health of
Boston Children's Hospital [83]
● Polycystic Ovary Syndrome: A Guide for Families – From the Pediatric Endocrine Society
(PES) and the American Academy of Pediatrics (AAP) [84]
SOCIETY GUIDELINE LINKS
Links to society and government-sponsored guidelines from selected countries and regions
around the world are provided separately. (See "Society guideline links: Polycystic ovary
syndrome" and "Society guideline links: Hirsutism".)
INFORMATION FOR PATIENTS
UpToDate offers two types of patient education materials, "The Basics" and "Beyond the
Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th
grade reading level, and they answer the four or five key questions a patient might have
about a given condition. These articles are best for patients who want a general overview and
who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are
longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th
grade reading level and are best for patients who want in-depth information and are
comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to
print or e-mail these topics to your patients. (You can also locate patient education articles on
a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
● Basics topic (see "Patient education: Polycystic ovary syndrome (The Basics)")
● Beyond the Basics topic (see "Patient education: Polycystic ovary syndrome (PCOS)
(Beyond the Basics)")
SUMMARY
● The evaluation for polycystic ovary syndrome (PCOS) begins with a focused clinical
evaluation for the presence of hirsutism (or hirsutism equivalents, such as acne that is
resistant to topical or oral antibiotic therapy) and menstrual abnormality ( table 1).
Some patients may present with a chief complaint of acanthosis nigricans or obesity
before the more classical manifestations develop. (See 'Indications for evaluation' above.)
● The clinical evaluation is followed by laboratory testing for common causes of abnormal
menses, including testing for androgen excess with total or free testosterone (
algorithm 1). (See 'History and physical examination' above and 'Screening tests to
detect common causes of abnormal menses' above.)
● If serum free testosterone levels are normal (in the absence of oral contraceptives), the
diagnosis of PCOS is unlikely. However, the possibility of PCOS in an adolescent should not
be fully dismissed until menses normalize and androgen levels are persistently normal.
(See 'Testing for hyperandrogenemia' above.)
● If serum levels of total and free testosterone are elevated, a focused history and physical
examination should be performed to exclude other hyperandrogenic disorders. Expert
practice varies regarding the extent and timing of further laboratory evaluation. In my
practice, I perform a simple screening battery of endocrine tests and ultrasonography at
this stage ( algorithm 2 and table 3). Other experts measure 17-
hydroxyprogesterone (at 8 AM) in many or all patients but perform the other screening
tests only in patients with atypical features, such as Cushingoid features, galactorrhea, or
virilization. (See 'Screening tests to exclude common non-PCOS causes of
hyperandrogenemia' above.)
• If the results of the endocrine screening panel are normal, the diagnosis of PCOS is
confirmed with a high level of certainty ( table 2). Any abnormal results suggest
that the hyperandrogenism is caused by a disorder other than PCOS. (See 'Endocrine
screening panel' above and 'Diagnosis' above.)
• The primary purpose of ultrasonography is to exclude the rare but serious virilizing
ovarian tumor that can mimic PCOS. Determining whether the ovaries are polycystic
is not helpful for the diagnosis of PCOS, because of the high frequency of polycystic-
appearing ovaries in adolescents with or without PCOS. (See 'Ultrasonography'
above.)
● Patients with atypical features, such as virilization, unexplained congenital or familial

hyperandrogenism, or unresponsiveness to standard PCOS therapy may have a rare
virilizing disorder rather than PCOS. In such cases, we suggest evaluation for rare
disorders mimicking PCOS, including the endocrine screening panel described above (if
not already done) and a dexamethasone androgen-suppression test (DAST) (
algorithm 3). (See 'Further endocrine evaluation for rare disorders mimicking PCOS'
above.)
● Once a diagnosis of PCOS has been established, it is important to identify and monitor for
abnormal glucose tolerance, type 2 diabetes, and other features of the metabolic
syndrome. This is because PCOS is a risk factor for the early development of these
disorders. Immediate family members are also at risk for these metabolic dysfunctions,
and premenopausal mothers and sisters are at risk for PCOS. (See 'Additional evaluation
of PCOS patients' above and 'Evaluation of family members' above.)
Use of UpToDate is subject to the Subscription and License Agreement.
REFERENCES
1. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary
syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745.
2. Rosenfield RL. Perspectives on the International Recommendations for the Diagnosis

and Treatment of Polycystic Ovary Syndrome in Adolescence. J Pediatr Adolesc Gynecol
2020.
3. Rosenfield RL. What every physician should know about polycystic ovary syndrome.
Dermatol Ther 2008; 21:354.
4. Witchel SF, Oberfield S, Rosenfield RL, et al. The Diagnosis of Polycystic Ovary Syndrome
during Adolescence. Horm Res Paediatr 2015.
5. Rosenfield RL. The Diagnosis of Polycystic Ovary Syndrome in Adolescents. Pediatrics

2015; 136:1154.
6. Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium Update:

Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in
Adolescence. Horm Res Paediatr 2017; 88:371.
7. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international
evidence-based guideline for the assessment and management of polycystic ovary
syndrome. Fertil Steril 2018; 110:364.
8. Ibáñez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers

and time course in adolescence. J Clin Endocrinol Metab 1999; 84:2691.
9. Risal S, Pei Y, Lu H, et al. Prenatal androgen exposure and transgenerational

susceptibility to polycystic ovary syndrome. Nat Med 2019; 25:1894.
10. Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol Metab Clin
North Am 2005; 34:677.
11. Rosenfield RL, Mortensen M, Wroblewski K, et al. Determination of the source of

androgen excess in functionally atypical polycystic ovary syndrome by a short
dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod
2011; 26:3138.
12. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in
Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin
Endocrinol Metab 2018; 103:1233.
13. Auchus RJ. Steroid assays and endocrinology: best practices for basic scientists.
Endocrinology 2014; 155:2049.
14. Rosner W, Vesper H, Endocrine Society, et al. Toward excellence in testosterone testing: a
consensus statement. J Clin Endocrinol Metab 2010; 95:4542.
15. Goodman NF, Cobin RH, Futterweit W, et al. AMERICAN ASSOCIATION OF CLINICAL
ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN
EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST
PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--
PART 1. Endocr Pract 2015; 21:1291.
16. Legro RS, Schlaff WD, Diamond MP, et al. Total testosterone assays in women with
polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol
Metab 2010; 95:5305.
17. Salameh WA, Redor-Goldman MM, Clarke NJ, et al. Specificity and predictive value of
circulating testosterone assessed by tandem mass spectrometry for the diagnosis of
polycystic ovary syndrome by the National Institutes of Health 1990 criteria. Fertil Steril
2014; 101:1135.
18. Tosi F, Fiers T, Kaufman JM, et al. Implications of Androgen Assay Accuracy in the
Phenotyping of Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2016;
101:610.
19. Moll GW Jr, Rosenfield RL. Testosterone binding and free plasma androgen
concentrations under physiological conditons: chararacterization by flow dialysis
technique. J Clin Endocrinol Metab 1979; 49:730.
20. Rosenfield RL, Moll GW. The role of proteins in the distribution of plasma androgens and
estradiol. In: Androgenization in women, Molinatti G, Martini L, James V (Eds), Raven Pres
s, New York 1983. p.25-45.
21. Pugeat M, Nader N, Hogeveen K, et al. Sex hormone-binding globulin gene expression in
the liver: drugs and the metabolic syndrome. Mol Cell Endocrinol 2010; 316:53.
22. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex
hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J
Clin Endocrinol Metab 1991; 72:83.
23. Simó R, Barbosa-Desongles A, Lecube A, et al. Potential role of tumor necrosis factor-α in
downregulating sex hormone-binding globulin. Diabetes 2012; 61:372.
24. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the
estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84:3666.
25. Fiers T, Wu F, Moghetti P, et al. Reassessing Free-Testosterone Calculation by Liquid

Chromatography-Tandem Mass Spectrometry Direct Equilibrium Dialysis. J Clin
26. Sharma A, Kapoor E, Singh RJ, et al. Diagnostic Thresholds for Androgen-Producing
Tumors or Pathologic Hyperandrogenism in Women by Use of Total Testosterone
Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry. Clin

Chem 2018; 64:1636.
27. Abraham GE. Ovarian and adrenal contribution to peripheral androgens during the
menstrual cycle. J Clin Endocrinol Metab 1974; 39:340.
28. Rosenfield RL, Helke JC. Small diurnal and episodic fluctuations of the plasma free
testosterone level in normal women. Am J Obstet Gynecol 1974; 120:461.
29. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and
management. Am J Obstet Gynecol 1981; 140:815.
30. ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin No. 108:
Polycystic ovary syndrome. Obstet Gynecol 2009; 114:936.
31. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary
syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;
98:4565.
32. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003

consensus on diagnostic criteria and long-term health risks related to polycystic ovary
syndrome. Fertil Steril 2004; 81:19.
33. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for
the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456.
34. Rosenfield RL, Cohen RM, Talerman A. Lipid cell tumor of the ovary in reference to adult-
onset congenital adrenal hyperplasia and polycystic ovary syndrome. A case report. J
Reprod Med 1987; 32:363.
35. Escobar-Morreale HF, Sanchón R, San Millán JL. A prospective study of the prevalence of
nonclassical congenital adrenal hyperplasia among women presenting with
hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008; 93:527.
36. Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: a comparison of
polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia.
Fertil Steril 2010; 94:684.
37. Carmina E, Dewailly D, Escobar-Morreale HF, et al. Non-classic congenital adrenal

hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on
adolescent and adult women. Hum Reprod Update 2017; 23:580.
38. Livadas S, Dracopoulou M, Dastamani A, et al. The spectrum of clinical, hormonal and
molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia
caused by mutations of the CYP21A2 gene. Clin Endocrinol (Oxf) 2015; 82:543.
39. Elhassan YS, Idkowiak J, Smith K, et al. Causes, Patterns, and Severity of Androgen Excess
in 1205 Consecutively Recruited Women. J Clin Endocrinol Metab 2018; 103:1214.
40. Lavery GG, Walker EA, Tiganescu A, et al. Steroid biomarkers and genetic studies reveal
inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone
reductase deficiency. J Clin Endocrinol Metab 2008; 93:3827.
41. Lawson AJ, Walker EA, Lavery GG, et al. Cortisone-reductase deficiency associated with
heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1. Proc Natl Acad
Sci U S A 2011; 108:4111.
42. Glickman SP, Rosenfield RL, Bergenstal RM, Helke J. Multiple androgenic abnormalities,
including elevated free testosterone, in hyperprolactinemic women. J Clin Endocrinol
Metab 1982; 55:251.
43. Filho RB, Domingues L, Naves L, et al. Polycystic ovary syndrome and hyperprolactinemia
are distinct entities. Gynecol Endocrinol 2007; 23:267.
44. Kaltsas GA, Androulakis II, Tziveriotis K, et al. Polycystic ovaries and the polycystic ovary
syndrome phenotype in women with active acromegaly. Clin Endocrinol (Oxf) 2007;
67:917.
45. Littlejohn EE, Weiss RE, Deplewski D, et al. Intractable early childhood obesity as the
initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary
syndrome. J Pediatr Endocrinol Metab 2007; 20:41.
46. Screening and Management of the Hyperandrogenic Adolescent: ACOG Committee

Opinion, Number 789. Obstet Gynecol 2019; 134:e106.
47. Bremer AA. Polycystic ovary syndrome in the pediatric population. Metab Syndr Relat
Disord 2010; 8:375.
48. Pascale MM, Pugeat M, Roberts M, et al. Androgen suppressive effect of GnRH agonist in
ovarian hyperthecosis and virilizing tumours. Clin Endocrinol (Oxf) 1994; 41:571.
49. Prassopoulos V, Laspas F, Vlachou F, et al. Leydig cell tumour of the ovary localised with
positron emission tomography/computed tomography. Gynecol Endocrinol 2011; 27:837.
50. Rosenfield RL. The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum. J
Pediatr Adolesc Gynecol 2015; 28:412.
51. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary:
international consensus definitions. Hum Reprod Update 2003; 9:505.
52. Bentzen JG, Forman JL, Johannsen TH, et al. Ovarian antral follicle subclasses and anti-
mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab 2013;
98:1602.
53. Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian
morphology: a task force report from the Androgen Excess and Polycystic Ovary
Syndrome Society. Hum Reprod Update 2014; 20:334.
54. Kenigsberg LE, Agarwal C, Sin S, et al. Clinical utility of magnetic resonance imaging and
ultrasonography for diagnosis of polycystic ovary syndrome in adolescent girls. Fertil
Steril 2015; 104:1302.
55. Villarroel C, Merino PM, López P, et al. Polycystic ovarian morphology in adolescents with
regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum
Reprod 2011; 26:2861.
56. Merino PM, Villarroel C, Jesam C, et al. New Diagnostic Criteria of Polycystic Ovarian
Morphology for Adolescents: Impact on Prevalence and Hormonal Profile. Horm Res
Paediatr 2017; 88:401.
57. Bidet M, Bellanné-Chantelot C, Galand-Portier MB, et al. Clinical and molecular

characterization of a cohort of 161 unrelated women with nonclassical congenital
adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin
58. Ambroziak U, Kępczyńska-Nyk A, Kuryłowicz A, et al. The diagnosis of nonclassic

congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal
or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis.
Clin Endocrinol (Oxf) 2016; 84:23.
59. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of
functional ovarian hyperandrogenism due to dysregulation of androgen secretion.
Endocr Rev 1995; 16:322.
60. Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic
proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab
2002; 87:2611.
61. Joehrer K, Geley S, Strasser-Wozak EM, et al. CYP11B1 mutations causing non-classic
adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet 1997; 6:1829.
62. Rosenfield RL, Wroblewski K, Padmanabhan V, et al. Antimüllerian hormone levels are
independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril
2012; 98:242.
63. Hart R, Doherty DA, Norman RJ, et al. Serum antimullerian hormone (AMH) levels are
elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome
(PCOS). Fertil Steril 2010; 94:1118.
64. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The
Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev
2016; 37:467.
65. Gorsic LK, Kosova G, Werstein B, et al. Pathogenic Anti-Müllerian Hormone Variants in
Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2017; 102:2862.
66. Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of
time to menopause in late reproductive age women. J Clin Endocrinol Metab 2012;
97:1673.
67. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pituitary-ovarian responses to
nafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989; 320:559.
68. Barnes RB, Ehrmann DA, Brigell DF, Rosenfield RL. Ovarian steroidogenic responses to
gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with
adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid
dehydrogenase deficiency. J Clin Endocrinol Metab 1993; 76:450.
69. Rosenfield RL, Ehrmann DA, Littlejohn EE. Adolescent polycystic ovary syndrome due to
functional ovarian hyperandrogenism persists into adulthood. J Clin Endocrinol Metab
2015; 100:1537.
70. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of
irregular menses and elevated androgen measurements at high risk for worsening
cardiovascular event-free survival: results from the National Institutes of Health--
National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome
Evaluation. J Clin Endocrinol Metab 2008; 93:1276.
71. Fauser BC, Bouchard P. Uncertainty remains in women with PCOS regarding the
increased incidence of cardiovascular disease later in life, despite the indisputable
presence of multiple cardiovascular risk factors at a young age. J Clin Endocrinol Metab
2011; 96:3675.
72. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of
polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS
Consensus Workshop Group. Fertil Steril 2012; 97:28.
73. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing

Committee. American Association of Clinical Endocrinologists Position Statement on
Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract
2005; 11:126.
74. Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary
syndrome--a position statement of the Androgen Excess Society. J Clin Endocrinol Metab
2007; 92:4546.
75. Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent
polycystic ovary syndrome to parental metabolic syndrome. J Clin Endocrinol Metab
2006; 91:1275.
76. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an
increased risk of the metabolic syndrome associated with increasing androgen levels
independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91:492.
77. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance
and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141.
78. Farhi DC, Nosanchuk J, Silverberg SG. Endometrial adenocarcinoma in women under 25
years of age. Obstet Gynecol 1986; 68:741.
79. Piltonen TT, Chen J, Erikson DW, et al. Mesenchymal stem/progenitors and other
endometrial cell types from women with polycystic ovary syndrome (PCOS) display
inflammatory and oncogenic potential. J Clin Endocrinol Metab 2013; 98:3765.
80. Legro RS, Driscoll D, Strauss JF 3rd, et al. Evidence for a genetic basis for
hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998;
95:14956.
81. Franks S, Webber LJ, Goh M, et al. Ovarian morphology is a marker of heritable
biochemical traits in sisters with polycystic ovaries. J Clin Endocrinol Metab 2008;
93:3396.
82. Yilmaz B, Vellanki P, Ata B, Yildiz BO. Diabetes mellitus and insulin resistance in mothers,
fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic
review and meta-analysis. Fertil Steril 2018; 110:523.
83. Center for Young Women's Health. PCOS (polycystic ovary syndrome). Available at: http
s://youngwomenshealth.org/2014/02/25/polycystic-ovary-syndrome/ (Accessed on Marc
h 15, 2018).
84. Pediatric Endocrine Society and the American Academy of Pediatrics: Polycystic Ovary Sy
ndrome: A guide for Patients and Parents. Available at: https://www.pedsendo.org/asset
s/patients_families/Educational_Materials/PolycysticOvarySyndrome.pdf (Accessed on M
arch 15, 2018).
Topic 94182 Version 27.0

Diagnostic Evaluation of Polycystic Ovary Syndrome in Adolescents - UpToDate

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Diagnostic Evaluation of Polycystic Ovary Syndrome in Adolescents - UpToDate

Uploaded by

Copyright:

Available Formats

21/10/2020 Diagnostic evaluation of polycystic ovary syndrome in adolescents - UpToDate

Author: Robert L Rosenfield, MD

INDICATIONS FOR EVALUATION

● An abnormal degree of hirsutism or a hirsutism equivalent, such as inflammatory acne

● Menstrual abnormality (persistent amenorrhea or oligomenorrhea, or excessive uterine

In my pediatric endocrinology practice, I typically order most of these screening tests

● Diagnosis – Demonstration of persistent hyperandrogenism in a patient with a

Lack of hyperandrogenemia effectively rules out the diagnosis of PCOS in adolescents.

BASIC DIAGNOSTIC APPROACH

History and physical examination — The evaluation starts with a thorough assessment of

Testing for hyperandrogenemia — Testing for testosterone and/or free testosterone should

For patients with severe or rapidly progressive hyperandrogenism, measurement of

Considerations for testosterone assays — Persistent serum testosterone elevation above

• The serum free testosterone concentration is approximately 50 percent more

Interpretation of testosterone levels — The normal upper limit for serum total

as 3-beta-hydroxysteroid dehydrogenase. They normalize androgens in PCOS and also have

Screening tests to detect common causes of abnormal menses — Most patients

Initial screening for patients with a menstrual abnormality should include:

● Beta-human chorionic gonadotropin (beta-hCG) – Pregnancy should be excluded in all

● Chronic disease panel – Complete blood count, erythrocyte sedimentation rate or C-

● Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) – Slightly elevated

● Prolactin – Hyperprolactinemia is a cause of gonadotropin deficiency; it is not

Screening tests to exclude common non-PCOS causes of hyperandrogenemia — If serum

● Early-morning 17-hydroxyprogesterone (17OHP) – An 8 AM 17OHP level is a good

• Early-morning sampling is critical to detect the 17OHP elevation of NCCAH because it

• It is important to obtain the screening sample when the patient is amenorrheic or

The measurement of other androgens, such as androstenedione, is ordinarily of little

Ultrasonography — The primary purpose of ultrasonography in the hyperandrogenemic

● The role of ultrasonography in the differential diagnosis of PCOS – Practice varies as

● Ultrasonographic criteria for polycystic ovary morphology (PCOM) – The

It is also best to confirm the persistence of hyperandrogenism in order to avoid labeling as

FURTHER ENDOCRINE EVALUATION FOR RARE DISORDERS MIMICKING

Some endocrinologists perform additional testing in hyperandrogenemic patients to detect

Our suggested approach to a more comprehensive diagnostic endocrine evaluation (

progressive hirsutism), unexplained congenital or familial hyperandrogenism, or

Dexamethasone androgen-suppression test — The responses of androgens (testosterone

● Baseline levels of steroid intermediates, such as 17-hydroxypregnenolone (17OHP), 11-

● The DAST is interpreted as follows:

• If testosterone excess is not suppressed by dexamethasone, but cortisol and DHEAS

• If neither androgen (testosterone and DHEAS) excess nor glucocorticoids are

• If both androgens (testosterone and DHEAS) and glucocorticoids are suppressed

Cosyntropin (ACTH) stimulation test — The responses of steroid intermediates on the

• Mildly elevated responses of 17-hydroxypregnenolone and DHEA are characteristic of

• Nonclassic 11-beta-hydroxylase deficiency is a rare mime of PCOS [61]. Only an 11-

● Gonadotropin-releasing hormone (GnRH) agonist test – In patients with PCOS,

ADDITIONAL EVALUATION OF PCOS PATIENTS

Once a diagnosis of PCOS has been established, the possibility of insulin-resistance

Glucose tolerance should be monitored regularly because a substantial number of women

EVALUATION OF FAMILY MEMBERS

SOCIETY GUIDELINE LINKS

INFORMATION FOR PATIENTS

a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

● Patients with atypical features, such as virilization, unexplained congenital or familial

Use of UpToDate is subject to the Subscription and License Agreement.

2. Rosenfield RL. Perspectives on the International Recommendations for the Diagnosis

5. Rosenfield RL. The Diagnosis of Polycystic Ovary Syndrome in Adolescents. Pediatrics

6. Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium Update:

8. Ibáñez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers

9. Risal S, Pei Y, Lu H, et al. Prenatal androgen exposure and transgenerational

11. Rosenfield RL, Mortensen M, Wroblewski K, et al. Determination of the source of

25. Fiers T, Wu F, Moghetti P, et al. Reassessing Free-Testosterone Calculation by Liquid

Concentrations Measured by Liquid Chromatography-Tandem Mass Spectrometry. Clin